StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen Other Residual Products (8-K Schedule) by Quarter

Other Residual Products (8-K Schedule) — Worldwide ($M) ($M)

QuarterlyAnnual

Amgen Other Residual Products (8-K Schedule): $351M in Q2 2026, up 5.1% from a year earlier.

Latest, Q2 2026
351
Period ended Jun 30, 2026
Change on a year earlier
+5.1%
334 in Q2 2025
History
39 quarters
Since Q4 2016
Sources
35
Documents cited below

Where the Q2 2026 figure comes from

“|| Other products (2) | 304 | 47 | 351 | 334 | 5%”

Source: Form 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗

Reported in Form 8-K Product Sales Detail Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOther Residual Products (8-K Schedule) — Worldwide ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026351+5.1%Form 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 2026315-7.4%Form 8-K (amgn-20260331earningsrelea.htm, filed 2026-04-30) ↗
Q4 2025Dec 31, 2025320-11.4%Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 2025317+12.8%Form 8-K (amgn-20250930earningsrelea.htm, filed 2025-11-04) ↗
Q2 2025Jun 30, 2025334-3.5%Form 8-K (amgn-20250630earningsrelea.htm, filed 2025-08-05) ↗
Q1 2025Mar 31, 2025340-4.8%Form 8-K (amgn-20250331earningsrelea.htm, filed 2025-05-01) ↗
Q4 2024Dec 31, 2024361+106.3%Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗
Q3 2024Sep 30, 2024281+68.3%Form 8-K (amgn-20240930earningsrelea.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 2024346+98.9%Form 8-K (amgn-20240630earningsrelea.htm, filed 2024-08-06) ↗
Q1 2024Mar 31, 2024357+85.0%Form 8-K (amgn-20240331earningsrelea.htm, filed 2024-05-02) ↗
Q4 2023Dec 31, 2023175+47.1%Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗
Q3 2023Sep 30, 2023167+46.5%Form 8-K (amgn-2023930earningsrelease.htm, filed 2023-10-31) ↗
Q2 2023Jun 30, 2023174+54.0%Form 8-K (amgn-2023630earningsrelease.htm, filed 2023-08-03) ↗
Q1 2023Mar 31, 2023193+127.1%Form 8-K (amgn-2023331earningsrelease.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 2022119+12.3%Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗
Q3 2022Sep 30, 2022114+22.6%Form 8-K (amgn-2022930earningsrelease.htm, filed 2022-11-03) ↗

Breakdown

What makes up other Residual Products (8-K Schedule)

Cite this data

StockData. (2026). Amgen Other Residual Products (8-K Schedule) ($M), quarterly Q4 2016–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-other-8k-ww

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.